NTRP Neurotrope Inc.

+0.1  (+2%)
Previous Close 5.57
Open 5.56
Price To Book 3.48
Market Cap 73,832,143
Shares 13,021,542
Volume 124,273
Short Ratio
Av. Daily Volume 98,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released May 1, 2017 - primary endpoint not met.
Alzheimer's disease
Phase 2 data due 3Q 2019.
Alzheimer's disease

Latest News

  1. Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
  2. Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
  3. Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
  4. Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
  5. Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
  6. Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019
  7. Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
  8. Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
  9. Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%
  10. Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel
  11. Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer
  12. Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease
  13. Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
  14. Neurotrope Reports Year End 2018 Financial Results
  15. Neurotrope to Participate in the BIO CEO & Investor Conference
  16. Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute
  17. Neurotrope to Participate in the Sachs Associates 2nd Annual Neuroscience Innovation Forum
  18. Biotech company offering Alzheimer’s disease patients hope with new drug
  19. Neurotrope Announces the Appointment of Two New Board Members
  20. Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease